Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer

Lauren Folgosa Cooley, Kimberly A. McLaughlin, Joshua J. Meeks*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.

Original languageEnglish (US)
Pages (from-to)35-46
Number of pages12
JournalUrologic Clinics of North America
Volume47
Issue number1
DOIs
StatePublished - Feb 2020

Fingerprint

Urinary Bladder Neoplasms
Mutation
Investigational Therapies
Bacillus
Neoplasms
Technology
Recurrence
Drug Therapy
Therapeutics
Research

Keywords

  • BCG
  • Bladder cancer
  • Genomics
  • Immunotherapy
  • Mutation

ASJC Scopus subject areas

  • Urology

Cite this

Cooley, Lauren Folgosa ; McLaughlin, Kimberly A. ; Meeks, Joshua J. / Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer. In: Urologic Clinics of North America. 2020 ; Vol. 47, No. 1. pp. 35-46.
@article{13c12f71a82642848370868454669f13,
title = "Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer",
abstract = "Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Gu{\'e}rin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.",
keywords = "BCG, Bladder cancer, Genomics, Immunotherapy, Mutation",
author = "Cooley, {Lauren Folgosa} and McLaughlin, {Kimberly A.} and Meeks, {Joshua J.}",
year = "2020",
month = "2",
doi = "10.1016/j.ucl.2019.09.006",
language = "English (US)",
volume = "47",
pages = "35--46",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "1",

}

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer. / Cooley, Lauren Folgosa; McLaughlin, Kimberly A.; Meeks, Joshua J.

In: Urologic Clinics of North America, Vol. 47, No. 1, 02.2020, p. 35-46.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer

AU - Cooley, Lauren Folgosa

AU - McLaughlin, Kimberly A.

AU - Meeks, Joshua J.

PY - 2020/2

Y1 - 2020/2

N2 - Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.

AB - Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.

KW - BCG

KW - Bladder cancer

KW - Genomics

KW - Immunotherapy

KW - Mutation

UR - http://www.scopus.com/inward/record.url?scp=85075073932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075073932&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2019.09.006

DO - 10.1016/j.ucl.2019.09.006

M3 - Review article

C2 - 31757298

AN - SCOPUS:85075073932

VL - 47

SP - 35

EP - 46

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 1

ER -